Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Athersys, Inc.
< Previous
1
2
Next >
Athersys Reports Third Quarter 2023 Financial Results and Business Highlights
November 16, 2023
From
Athersys, Inc.
Via
Business Wire
Tickers
ATHX
OTC
Athersys Extends Near Term Liquidity with Proceeds from Warrant Inducement and Global ARDS License with Healios to Explore Strategic Alternatives
October 16, 2023
From
Athersys, Inc.
Via
Business Wire
Tickers
ATHX
Athersys Reports Interim Analysis Results of MASTERS-2 Clinical Study with MultiStem in Ischemic Stroke, Signs Memorandum of Understanding (MOU) for Global ARDS License with Healios
October 10, 2023
From
Athersys, Inc.
Via
Business Wire
Tickers
ATHX
Athersys Licenses its Animal Health Assets to Ardent Animal Health
October 03, 2023
From
Athersys, Inc.
Via
Business Wire
Tickers
ATHX
Athersys Director Jane Wasman Appointed Board Chair
October 02, 2023
From
Athersys, Inc.
Via
Business Wire
Tickers
ATHX
Grant Awarded to Newcastle University to Research Athersys’ MultiStem® in Machine Perfusion Prior to Kidney Transplantation
September 06, 2023
From
Athersys, Inc.
Via
Business Wire
Tickers
ATHX
Athersys, Inc. Announces Pricing of $3.5 Million Public Offering
August 17, 2023
From
Athersys, Inc.
Via
Business Wire
Tickers
ATHX
Athersys Reports Second Quarter 2023 Financial Results and Business Highlights
August 16, 2023
From
Athersys, Inc.
Via
Business Wire
Tickers
ATHX
Athersys Appoints Neema Mayhugh, PhD to its Board of Directors
August 11, 2023
From
Athersys, Inc.
Via
Business Wire
Tickers
ATHX
Athersys to Host Business Update Conference Call on August 9th
July 31, 2023
From
Athersys, Inc.
Via
Business Wire
Tickers
ATHX
Patient Enrollment Begins in Third and Final Cohort of the Phase 2 MATRICS-1 Clinical Study Evaluating Athersys’ MultiStem® Following Hemorrhagic Trauma
June 01, 2023
From
Athersys, Inc.
Via
Business Wire
Tickers
ATHX
Athersys Restructures Debt with Supplier
May 23, 2023
From
Athersys, Inc.
Via
Business Wire
Tickers
ATHX
Athersys Reports First Quarter 2023 Financial Results and Business Highlights
May 18, 2023
From
Athersys, Inc.
Via
Business Wire
Tickers
ATHX
Athersys to Participate in Three Upcoming Conferences
May 08, 2023
From
Athersys, Inc.
Via
Business Wire
Tickers
ATHX
Athersys to Participate in The Cellular Therapies and Transfusion Medicine in Trauma and Critical Care Conference
May 01, 2023
From
Athersys, Inc.
Via
Business Wire
Tickers
ATHX
Athersys to Participate in The American Society for Neural Therapy and Repair Annual Conference
April 21, 2023
From
Athersys, Inc.
Via
Business Wire
Tickers
ATHX
Athersys, Inc. Announces Closing of $3.7 Million Registered Direct Offering and Concurrent Private Placement
April 19, 2023
From
Athersys, Inc.
Via
Business Wire
Tickers
ATHX
Athersys, Inc. Announces $3.7 Million Registered Direct Offering and Concurrent Private Placement
April 18, 2023
From
Athersys, Inc.
Via
Business Wire
Tickers
ATHX
Athersys to Host Business Update Conference Call on April 20th
April 10, 2023
From
Athersys, Inc.
Via
Business Wire
Tickers
ATHX
Athersys Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
March 31, 2023
From
Athersys, Inc.
Via
Business Wire
Tickers
ATHX
Athersys Announces Successful Type B Meeting with the FDA
March 22, 2023
From
Athersys, Inc.
Via
Business Wire
Tickers
ATHX
Athersys Expands IP Protection with First New Patent for SIFU® Technology
February 28, 2023
From
Athersys, Inc.
Via
Business Wire
Tickers
ATHX
Athersys Granted Clinical Type B Meeting with FDA for MASTERS-2 Clinical Trial Protocol Discussion
February 14, 2023
From
Athersys, Inc.
Via
Business Wire
Tickers
ATHX
Athersys to Host Business Update Conference Call on February 14th
February 02, 2023
From
Athersys, Inc.
Via
Business Wire
Tickers
ATHX
Athersys to Participate in International Stroke Conference and BioProcess International
January 30, 2023
From
Athersys, Inc.
Via
Business Wire
Tickers
ATHX
Athersys to Participate in Advanced Therapies Week and Allogeneic Cell Therapies Summit Europe in January
January 11, 2023
From
Athersys, Inc.
Via
Business Wire
Tickers
ATHX
Athersys Provides MultiStem Clinical Update
January 09, 2023
From
Athersys, Inc.
Via
Business Wire
Tickers
ATHX
Athersys Appoints Joseph Nolan to Its Board of Directors
January 05, 2023
From
Athersys, Inc.
Via
Business Wire
Tickers
ATHX
Athersys Reports Third Quarter 2022 Financial Results and Provides Business Update
November 15, 2022
From
Athersys, Inc.
Via
Business Wire
Tickers
ATHX
Athersys to Present at Challenges and Opportunities for Mesenchymal Stem Cells Digital Conference and Participate in A.G.P.’s Biotech Conference
November 11, 2022
From
Athersys, Inc.
Via
Business Wire
Tickers
ATHX
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.